|
|
|
|
|
|
|
01.07.25 - 13:03
|
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025 (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique pas...
|
|
|
|
|
|
|
|
|
|
|
02.06.25 - 14:12
|
IQVIA Announces Offering of Senior Notes (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”).
The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.25 - 19:06
|
"Strong Demand" For Lilly′s Weight-Loss Drug Overshadowed By Guidance Cut, Shares Fall (ZeroHedge)
|
|
|
"Strong Demand" For Lilly's Weight-Loss Drug Overshadowed By Guidance Cut, Shares Fall
Eli Lilly & Co. shares fell in premarket trading in New York after the company slashed its full-year profit outlook, citing increased research and development expenses, despite posting first-quarter revenue and earnings that beat analysts' expectations, driven by strong demand for its anti-obesity drug, Mounjaro.
Goldman analysts, including Asad Haider, provided clients with a first take on Lilly's first-quarter earnings, indicating that 1Q25 results "slightly exceeded expectations."
LLY's 1Q25 earnings slightly exceeded expectations, where, encouragingly, the tirzepatide franchise (Zepbound + Mounjaro) came in at $6.15bn ahead of GS/Visible Alpha Consensus Data ($6bn), reflecting continued strong demand, partially offset by lower realized prices. We note that recent IQVIA data shows Zepbound momentum continuing into April. Performance was a bit uneven amongst other portfolio items...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
